Skip to main content

Advertisement

Table 3 Multivariate analysis of the prognosis of 251 patients with N0-category NPC and ENLNs using an adjusted Cox proportional hazards model

From: Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes

Variable RRFS DFS OS DMFS
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Gender (male vs. female) <0.001 0.666 1.548 0.530–4.525 0.424 1.089 0.223–5.307 0.916 1.562 0.340–7.182 0.567
Age (≥50 vs. <50 years) <0.001 0.583 2.318 0.998–5.386 0.051 7.955 1.916–33.026 0.004 2.821 0.892–8.919 0.077
Smoking (yes vs. no) 0.009 0.841 1.680 0.686–4.116 0.257 2.608 0.713–9.536 0.147 2.393 0.759–7.544 0.136
Drinking (yes vs. no) 0.001 0.870 0.350 0.047–2.632 0.308 <0.001 0.980 <0.001 0.985
Serum LDH level (<245 vs. ≥245 U/L) <0.001 0.857 4.689 1.370–16.050 0.014 15.445 3.224–73.992 0.001 5.794 1.258–26.693 0.024
Family history of cancer (yes vs. no) 132.973 0.585 0.764 0.302–1.933 0.570 0.199 0.034–1.172 0.074 0.602 0.160–2.270 0.454
BED (<72 vs. ≥72 Gy) 107,046.092 0.485 2.438 0.882–7.226 0.108 3.097 0.697–13.754 0.137 2.741 0.60–12.526 0.193
Chemotherapy (yes vs. no) <0.001 0.473 1.123 0.409–3.084 0.821 1.132 0.235–5.465 0.877 0.924 0.228–3.752 0.912
T category (T1–2 vs. T3–4) <0.001 0.539 1.204 0.510–2.842 0.672 2.984 0.649–13.720 0.160 1.497 0.468–4.794 0.497
ENLN diameter (<5.5 vs. ≥5.5 mm) <0.001 0.498 1.914 0.704–5.200 0.203 1.288 0.308–5.392 0.729 2.579 0.556–11.969 0.226
  1. RRFS regional relapse-free survival, DFS disease-free survival, OS overall survival, DMFS distant metastases-free survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, BED biological equivalent dose
  2. – No confidence interval